Legend Biotech (LEGN) EBT Margin (2019 - 2026)
Legend Biotech's (LEGN) quarterly EBT Margin came in at 17.63% in Q1 2026, up 3324.0% YoY from 0.51% in Q1 2025, and down 174.17% on a QoQ basis from 6.43% in Q4 2025.
Powered by 
Analysis
Legend Biotech (LEGN) EBT Margin (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of EBT Margin data on file, last reported at 17.63% in Q1 2026.
- Quarterly EBT Margin rose 3324.0% year-over-year to 17.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.84% (up 627.0% YoY) and the FY2025 annual result came in at 27.47%, down 226.0% from the prior year.
- EBT Margin fell to 17.63% in Q1 2026, from 6.43% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 21.77% in Q4 2024 to a low of 1612.82% in Q2 2022.
- A 5-year average of 199.29% and a median of 63.61% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin slumped 76081 bps — and 2023, when it surged 134167 bps.
- Tracing LEGN's EBT Margin over 5 years: stood at 491.16% in 2022, then jumped by 100 bps to 0.18% in 2023, then surged by 11883 bps to 21.77% in 2024, then tumbled by 130 bps to 6.43% in 2025, then plunged by 174 bps to 17.63% in 2026.
- The last three EBT Margin figures came in at 17.63% (Q1 2026), 6.43% (Q4 2025), and 14.35% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 14.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.32% |
| Mar 31, 2026 | -17.40% |
| Dec 31, 2025 | -6.43% |
| Sep 30, 2025 | -14.35% |
| Jun 30, 2025 | -48.92% |
| Mar 31, 2025 | -50.87% |
| Dec 31, 2024 | 21.77% |
| Sep 30, 2024 | -75.46% |
| Jun 30, 2024 | -9.63% |
| Mar 31, 2024 | -63.61% |
| Dec 31, 2023 | -184.75% |
| Sep 30, 2023 | -65.09% |
| Jun 30, 2023 | -271.16% |
| Mar 31, 2023 | -308.16% |
| Dec 31, 2022 | -491.16% |
| Sep 30, 2022 | -309.94% |
| Jun 30, 2022 | -1,612.82% |
| Mar 31, 2022 | -64.20% |
| Dec 31, 2021 | -1,044.23% |
| Sep 30, 2021 | -738.96% |